Regeneron Pharmaceuticals Inc

Looking for a prescription for success? Then this could be the stock for you. Regeneron is at the forefront of biotechnology that develops and commercializes life-transforming medicines. They are best known for their blockbuster drug Eylea, which is used to treat age-related macular degeneration—a leading cause of blindness in the elderly.

$573.45
(as of Apr 4, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Regeneron Pharmaceuticals Inc

Stock Price
$573.45
Ticker Symbol
REGN
Exchange
NASDAQ

Industry Information for Regeneron Pharmaceuticals Inc

Sector
Healthcare
Industry
Biotechnology

Company Description for Regeneron Pharmaceuticals Inc

Country
USA
Full Time Employees
15,106

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Fundamentals for Regeneron Pharmaceuticals Inc

Market Capitalization
$66,758,217,728
EBITDA
$4,627,999,744
Dividends per Share
$0
P/E Ratio
15.92
Forward P/E Ratio
13.51
Earnings per Share
$38.35
Earnings per Share Estimate Next Year
Profit Margin
31.07%
Shares Outstanding
107,508,000
Percent Owned by Insiders
1.58%
Percent Owned by Institutions
91.38%
52-Week High
52-Week Low

Technical Indicators for Regeneron Pharmaceuticals Inc

50-Day Moving Average
200-Day Moving Average
RSI
26.12
21.41

Analyst Ratings for Regeneron Pharmaceuticals Inc

Strong Buy
12
Buy
6
Hold
6
Sell
1
Strong Sell
0

News About Regeneron Pharmaceuticals Inc

Apr 2, 2025, 9:46 AM EST
We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. See more.
Apr 1, 2025, 11:50 AM EST
Shares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food and Drug Administration’s Center for Biologics Evaluation and Research, Peter Marks. See more.
Apr 1, 2025, 10:49 AM EST
For Immediate Release See more.
Mar 31, 2025, 10:10 AM EST
Intellia Therapeutics, Inc. See more.